Empreses emergents
2018
Flomics BiotechPotents diagnòstics de seqüenciació amb el suport de biomarcadors i bioinformàtica innovadors basats en ARN. La prova de sang multicàncer de Flomics troba canvis en els patrons d'expressió de les molècules d'ARN en circulació per detectar i cribrar el càncer abans que apareguin els primers símptomes.
Adreça
Carrer de Roc Boronat 31, 08005 Barcelona, Espanya
Dades financeres
Propietat CERCA
Barcelona, Spain
2000
Centre de Regulació Genòmica (CRG)
Àrees d'estat i deeptech
Estat de l'empresa i àrees de tecnologia profunda de l'empresaEstat de l'empresa
Àrea DeepTech
Informació sobre la spin-off
Descripció de l'empresa
Flomics is a biotechnology company operating in the field of genomics, bioinformatics and NGS. We are developing a novel multicancer screening solution to be implemented in the clinical practice. Flomics also provides a complete range of personalized genomic services, with a fully compliant molecular biology laboratory and specialized bioinformatics department. Flomics was founded in 2018 by researchers of the Center of Genomic Regulation (CRG) and the Pompeu Fabra University (UPF), and is currently located in the beautiful Barcelona Biomedical Research Park (PRBB) building.
Our Mission
To improve clinical practice development of a multi-disease detection test from a standard blood sample.
Our Mission
To improve clinical practice development of a multi-disease detection test from a standard blood sample.
Descripció del producte
Next-generation liquid biopsy
The study of circulating molecules present in blood is known as liquid biopsies, a field that has been constantly growing and evolving in the past decade. Blood is a carrier of several cell types, but also the recipient of biological information such as cell-free RNA (cfRNA). Because all organs shed RNA into the circulation, liquid biopsies are the perfect snapshot of what is happening to all organs at a specific time from a single blood draw.
At Flomics, we believe that RNAs are the best biomarkers available in circulation, allowing reliable diagnosis of complex diseases, even before the first symptoms appear.
Groundbreaking technology
Flomics test detects disease signatures in blood by combining Next-Generation Sequencing (NGS) of cell-free RNA molecules with powerful machine learning techniques.
The study of circulating molecules present in blood is known as liquid biopsies, a field that has been constantly growing and evolving in the past decade. Blood is a carrier of several cell types, but also the recipient of biological information such as cell-free RNA (cfRNA). Because all organs shed RNA into the circulation, liquid biopsies are the perfect snapshot of what is happening to all organs at a specific time from a single blood draw.
At Flomics, we believe that RNAs are the best biomarkers available in circulation, allowing reliable diagnosis of complex diseases, even before the first symptoms appear.
Groundbreaking technology
Flomics test detects disease signatures in blood by combining Next-Generation Sequencing (NGS) of cell-free RNA molecules with powerful machine learning techniques.